-
1.
公开(公告)号:US20230137816A1
公开(公告)日:2023-05-04
申请号:US17904031
申请日:2021-02-10
申请人: DEUTSCHES HERZZENTRUM MUENCHEN DES FREISTAATES BAYERN , Klinikum Rechts Der Isar der Technischen Universitaet Muenchen
IPC分类号: A61K31/451 , A61K31/496 , A61K31/4545 , A61K31/501 , A61K31/499 , A61K31/4995 , A61K31/5386 , A61K31/46 , A61P9/00 , A61K31/27 , A61K31/4725 , A61K31/454 , A61L31/10 , A61L29/08 , A61L31/16 , A61L29/16
摘要: The present invention relates to a medical device suitable for being inserted into the lumen of an anatomic structure of a subject, said medical device comprising means for administration of TRPC6 inhibitor, wherein said means comprises the TRPC6 inhibitor. The present invention further concerns a method of manufacturing a medical device suitable for being inserted into the lumen of an anatomic structure of a subject. Also, the invention relates to a TRPC6 inhibitor for use in the treatment or prevention of a disease associated with neointimal hyperplasia associated with the migration of smooth muscular cells. The invention also relates to a method of treating or preventing a disease associated with neointimal hyperplasia, said method comprising administering a TRPC6 inhibitor to a subject in need thereof. Also envisaged is a method of inhibiting migration of smooth muscle cells. The invention additionally relates to an in vitro test kit comprising: (a) small muscle cells (SMCs); (b) a surface suitable for SMC cultivation coated with a TRPC6 inhibitor. Also concerned is a pharmaceutical composition comprising a TRPC6 inhibitor and a pharmaceutically acceptable carrier.
-
公开(公告)号:US11638745B2
公开(公告)日:2023-05-02
申请号:US15573006
申请日:2016-05-20
IPC分类号: A61K38/18 , A61P25/00 , A61K47/68 , A61P9/10 , A61P25/28 , A61P9/00 , A61P9/04 , A01N1/02 , A61F7/00 , A61F7/02 , A61F7/10 , A61F7/12 , A61K9/00
摘要: A method of improving brain function in a hypothermic patient is provided. The method comprises administering to the patient an amount of a fibroblast growth factor 21 (FGF21) effective to increase RNA binding motif 3 (RBM3) production in nerve cells of the patient. The method is useful, for example, where the patient is or will be undergoing cardiac surgery or spinal surgery, such as requiring deep hypothermia circulatory arrest (DHCA), or is subject to an emergency preservation and resuscitation (EPR) method, or where a patient suffers from mild/moderate/severe traumatic brain injury (TBI), ventricular fibrillation cardiac arrest (VFCA), subarachnoid hemorrhage (SAH), subdural hematoma (SH), cerebral vasospasm, neonatal abusive head trauma (a.k.a. shaken baby syndrome), neonatal hypoxic ischemic encephalopathy (HIE), asphyxia cardiac arrest (ACA), treatment of spinal injury, prophylaxis in spinal surgery, stroke, and drug overdose.
-
公开(公告)号:US20230127345A1
公开(公告)日:2023-04-27
申请号:US18052814
申请日:2022-11-04
发明人: Sharon Shechter , Eliezer Zomer , Peter G. Traber , Raphael Nir , Joseph M. Johnson , Ryan George
IPC分类号: C07H19/056 , A61P1/16 , A61P9/00 , A61P13/12 , A61P11/00 , A61K31/7056 , A61K45/06
摘要: Aspects of the invention relate to novel synthetic compounds having a binding affinity with galectin proteins.
-
公开(公告)号:US20230115912A1
公开(公告)日:2023-04-13
申请号:US17931801
申请日:2022-09-13
申请人: CHEMOCENTRYX, INC.
发明人: Pingchen FAN , Christopher W. LANGE , Viengkham MALATHONG , Venkat Reddy MALI , Sreenivas PUNNA , Hiroko TANAKA , Yibin ZENG , Penglie ZHANG
IPC分类号: A61K31/437 , A61P37/00 , A61P35/00 , A61P9/00
摘要: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
-
公开(公告)号:US20230111558A1
公开(公告)日:2023-04-13
申请号:US17498722
申请日:2021-10-11
发明人: Jianghua LIU
IPC分类号: A61K36/537 , A61K36/258 , A61K31/122 , A61P9/10 , A61P9/00
摘要: A composition for preventing and treating heart dysfunction and its application thereof, including approximately 6-10% coenzyme Q10, approximately 40-45% Radix salviae Militiorrhizae and approximately 40-45% Radix notoginseng, which is prepared into an oral application such as tablets, capsules, granules or powders in sachets, pills, and oral solution. The extract of Radix salviae Militiorrhizae is a water-soluble extract of the root of Salvia miltiorrhiza Bunge and the powder of Radix notoginseng is a fine powder of the root of Panax notoginseng (Burk.). The composition can be prepared into a dietary supplement for improving heart function or a medicament for treating heart dysfunction by preventing heart failure, treating myocardial injury caused by hypoxia or reperfusion, treating abnormal heartbeat, treating palpitation, relieving pericardial edema, or treating palpitation and chest tightness caused by dysautonomia.
-
公开(公告)号:US20230094545A1
公开(公告)日:2023-03-30
申请号:US17799904
申请日:2021-02-26
申请人: AKAAL PHARMA PTY LTD
发明人: DAMIAN GROBELNY , GURMIT SINGH GILL
IPC分类号: A61K31/4245 , A61P9/00 , A61P17/04 , A61P29/00 , A61P25/02 , A61P25/28 , A61P1/04 , A61P19/02 , A61P17/06 , A61K9/00 , A61P37/08 , A61K9/20 , A61K9/06 , A61K9/08 , A61K9/70 , A61K31/455 , A61K31/355 , A61K31/573 , A61K31/196 , A61P17/02 , A61P17/10 , A61K45/06 , A61K47/10 , A61K47/06 , A61K47/12 , A61K47/14 , A61K47/44 , A61K47/22 , A61K47/38
摘要: The current invention is based on the determination that a S1P receptor modulator compound of formula (I): decreases the heart rate of a subject to which it is administered by about 5 beats/min or less daily, or about 4 beats/min or less daily, or about 3 beats/min or less daily, or about 2 beats/min or less daily, wherein the S1P receptor modulator is administered at an initial daily dosage which is substantially the same as the standard daily therapeutic dosage.
-
公开(公告)号:US20230087609A1
公开(公告)日:2023-03-23
申请号:US17797448
申请日:2021-02-18
发明人: Harald Horst Heinz Wilhelm Schmidt , Mahmoud Hassan Mahmoud Elbatrik , Thao-Vi Dao , Ana Isabel Casas Guijarro , Theodora Saridaki , Alexandra Petraina
IPC分类号: A61K31/506 , A61K31/137 , A61K31/197 , A61K31/416 , A61K31/427 , A61K31/4439 , A61K31/5377 , A61K45/06 , A61P9/00
摘要: The invention relates to a pharmaceutical composition comprising one or more stimulators of soluble guanylate cyclase (sGC), or a combination of at least one stimulator of sGC and at least one activator of sGC, for use in a method of treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3′,5′-guanosine monophosphate in the patient to be treated. The invention also relates to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. The invention also relates to a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator, for use in a method for the treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3′,5′-guanosine monophosphate in the patient to be treated. Furthermore, the invention relates to a kit comprising a pharmaceutical composition comprising one or more stimulators of sGC; a pharmaceutical composition comprising one or more stimulators of sGC and one or more activators of sGC; a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator; or to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator.
-
公开(公告)号:US20230067942A1
公开(公告)日:2023-03-02
申请号:US17796451
申请日:2021-01-27
发明人: Parag SHAH , Peter FERNANDES
摘要: Described are methods for reducing pulmonary resistance, reducing pulmonary pressure, and increasing pulmonary arterial compliance by providing a inhaled nitric oxide.
-
公开(公告)号:US20230055117A1
公开(公告)日:2023-02-23
申请号:US17893840
申请日:2022-08-23
发明人: Han Soo Park
IPC分类号: C12N1/20 , A23K50/50 , A23K10/18 , A23L33/135 , A61P1/16 , A61P9/00 , A61P3/06 , A61P3/10 , A61P29/00 , A61K35/747
摘要: The present invention relates to a novel strain of Lactobacillus fermentum LM1016 deposited with the Korean Culture Center of Microorganisms under accession number KCCM12468P. The novel strain of the present invention has an effect of treating or preventing cardiovascular diseases, obesity, fatty liver or diabetes mellitus.
The present invention relates to a composition comprising the strain, and the composition may be used in a pharmaceutical product, a health functional food, a dairy product, a fermented product, a food additive and an animal feed and the like.-
公开(公告)号:US20230048017A1
公开(公告)日:2023-02-16
申请号:US17685457
申请日:2022-03-03
发明人: Guangping Gao , Phillip Tai , Claudio Punzo , Haijiang Lin
IPC分类号: C12N15/86 , C07K14/005 , C12N7/00 , A61K35/76 , A61P9/00
摘要: Aspects of the disclosure relate to compositions and methods for expressing anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject. In some embodiments, the disclosure provides rAAVs comprising a capsid protein (e.g., AAV2 variants, AAV2/3 hybrid variants, AAV8 variants, etc.), and a transgene encoding an anti-VEGF agent (e.g., KH902) and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.
-
-
-
-
-
-
-
-
-